DK1383489T3 - Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neurodegeneative sygdomme - Google Patents

Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neurodegeneative sygdomme

Info

Publication number
DK1383489T3
DK1383489T3 DK02714977T DK02714977T DK1383489T3 DK 1383489 T3 DK1383489 T3 DK 1383489T3 DK 02714977 T DK02714977 T DK 02714977T DK 02714977 T DK02714977 T DK 02714977T DK 1383489 T3 DK1383489 T3 DK 1383489T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
neurodegenerative diseases
carbamate compounds
carbamate
Prior art date
Application number
DK02714977T
Other languages
Danish (da)
English (en)
Inventor
Boyu Zhao
Carlos R Plata-Salaman
Roy E Twyman
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1383489T3 publication Critical patent/DK1383489T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
DK02714977T 2001-02-27 2002-02-21 Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neurodegeneative sygdomme DK1383489T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
PCT/US2002/005541 WO2002067925A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
DK1383489T3 true DK1383489T3 (da) 2007-08-06

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02714977T DK1383489T3 (da) 2001-02-27 2002-02-21 Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neurodegeneative sygdomme

Country Status (27)

Country Link
US (3) US20020165273A1 (ru)
EP (1) EP1383489B1 (ru)
JP (1) JP4276840B2 (ru)
KR (1) KR100910928B1 (ru)
CN (1) CN1235579C (ru)
AR (1) AR035756A1 (ru)
AT (1) ATE361745T1 (ru)
BR (1) BR0207645A (ru)
CA (1) CA2439295C (ru)
CY (1) CY1106753T1 (ru)
CZ (1) CZ301203B6 (ru)
DE (1) DE60220043T2 (ru)
DK (1) DK1383489T3 (ru)
ES (1) ES2284845T3 (ru)
HK (2) HK1060516A1 (ru)
HU (1) HUP0303264A3 (ru)
IL (2) IL157591A0 (ru)
MX (1) MXPA03007718A (ru)
MY (1) MY138156A (ru)
NO (1) NO20033798L (ru)
NZ (1) NZ527990A (ru)
PL (1) PL364680A1 (ru)
PT (1) PT1383489E (ru)
RS (1) RS51055B (ru)
RU (1) RU2300373C2 (ru)
TW (1) TWI312679B (ru)
WO (1) WO2002067925A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470798B2 (en) * 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
ES2342185T3 (es) * 2004-09-16 2010-07-02 Janssen Pharmaceutica Nv Uso de (di)carbamatos de 2-fenil-1,2-etanodiol para el tratamiento de la epileptogenesis.
BRPI0516112A (pt) * 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
AU2005335241B9 (en) * 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
AU2007307029A1 (en) * 2006-10-06 2008-04-17 Transform Pharmaceuticals, Inc. Novel crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
CN101568362A (zh) * 2006-10-30 2009-10-28 詹森药业有限公司 治疗抑郁症的方法
CN101568333A (zh) * 2006-10-31 2009-10-28 詹森药业有限公司 广泛性发育障碍的治疗
ES2711619T3 (es) * 2010-07-02 2019-05-06 Bio Pharm Solutions Co Ltd Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20130060024A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
CN104136413B (zh) 2011-12-27 2016-10-26 比皮艾思药物研发有限公司 用于预防或治疗癫痫症的苯基氨基甲酸酯化合物
CN105164103B (zh) * 2013-03-12 2019-12-06 比皮艾思药物研发有限公司 苯基氨基甲酸酯化合物和含有其的预防或治疗记忆缺失相关疾病的组合物
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
US10351519B2 (en) * 2016-02-29 2019-07-16 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
EP3556365A4 (en) 2016-12-14 2020-06-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND FOR THE PREVENTION, RELIEF OR TREATMENT OF A DEMYLINATING DISEASE
MX2021003203A (es) * 2018-09-21 2021-05-27 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
JP2023539291A (ja) * 2020-08-31 2023-09-13 バイオ－ファーム ソリューションズ カンパニー リミテッド 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物
CA3191081A1 (en) 2020-09-10 2022-03-17 Yong Moon Choi Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
RU2300372C2 (ru) * 2001-02-27 2007-06-10 Орто-Макнейл Фармасьютикал, Инк. Карбаматы для применения для предотвращения или лечения биполярного расстройства
RU2302240C2 (ru) * 2001-02-27 2007-07-10 Орто-Макнейл Фармасьютикал, Инк. Производные карбаматов для предотвращения или лечения психотических нарушений
NZ551954A (en) * 2001-02-27 2008-07-31 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating movement disorders

Also Published As

Publication number Publication date
CA2439295C (en) 2010-05-25
WO2002067925A1 (en) 2002-09-06
JP2004523555A (ja) 2004-08-05
DE60220043T2 (de) 2008-01-10
EP1383489A1 (en) 2004-01-28
CN1235579C (zh) 2006-01-11
ES2284845T3 (es) 2007-11-16
US20020165273A1 (en) 2002-11-07
DE60220043D1 (de) 2007-06-21
JP4276840B2 (ja) 2009-06-10
CY1106753T1 (el) 2012-05-23
NO20033798D0 (no) 2003-08-26
HK1060516A1 (en) 2004-08-13
CN1503667A (zh) 2004-06-09
RS51055B (sr) 2010-10-31
NO20033798L (no) 2003-09-26
MXPA03007718A (es) 2004-11-12
KR20030076714A (ko) 2003-09-26
RS67403A (en) 2006-12-15
RU2003128982A (ru) 2005-03-10
PL364680A1 (en) 2004-12-13
BR0207645A (pt) 2004-12-28
CZ20032313A3 (cs) 2004-08-18
EP1383489B1 (en) 2007-05-09
RU2300373C2 (ru) 2007-06-10
HK1065486A1 (en) 2005-02-25
ATE361745T1 (de) 2007-06-15
IL157591A0 (en) 2004-03-28
NZ527990A (en) 2006-01-27
PT1383489E (pt) 2007-06-21
CA2439295A1 (en) 2002-09-06
AR035756A1 (es) 2004-07-07
KR100910928B1 (ko) 2009-08-06
HUP0303264A3 (en) 2012-07-30
CZ301203B6 (cs) 2009-12-09
US20090005442A1 (en) 2009-01-01
IL157591A (en) 2009-12-24
US20040171679A1 (en) 2004-09-02
HUP0303264A2 (hu) 2004-01-28
TWI312679B (en) 2009-08-01
MY138156A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
DK1383489T3 (da) Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neurodegeneative sygdomme
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK1446122T5 (da) Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
DK2412368T3 (da) Sammensætning til behandling af ar
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
DK1478358T3 (da) Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1556342T3 (da) Phenethanolaminderivat til behandling af respiratoriske sygdomme
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
DK1411917T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bevægelsesforstyrrelser
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1411926T3 (da) Integrininhibitorer til behandling af öjensygdomme
DK1694342T3 (da) Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
DK1401424T3 (da) Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af psykotiske forstyrrelser
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner